The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

Plus: Oracle posts strong quarterly results boosted by the company's artificial-intelligence investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting ...

Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its ...

Health-care companies rose amid deal activity. BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion.

Key developments in US health news include the release of new dietary guidelines, FDA approvals for bladder and lung cancer drugs, and significant policy shifts by U.S. Health Secretary Robert F.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...